Biologic Approaches to Treat Substance-Use Disorders

详细信息    查看全文

• 作者：Phil Skolnick¹ ; ^{phil.skolnick@nih.gov" class="auth_mail" title="E-mail the corresponding author}
• 关键词：substance use disorders ; cocaine ; methamphetamine ; nicotine ; vaccines ; monoclonal antibodies
• 刊名：Trends in Pharmacological Sciences
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：36
• 期：10
• 页码：628-635
• 全文大小：1328 K

文摘

In contrast to traditional pharmacodynamic approaches to treat substance-use disorders (SUDs), the use of biologics (vaccines, monoclonal antibodies, and genetically modified enzymes) is based on a pharmacokinetic principle: reduce the amount of (and, ideally, eliminate) abused drug entering the central nervous system (CNS). Preclinical studies indicate that biologics are effective in both facilitating abstinence and preventing relapse to abused substances ranging from nicotine to heroin. While data are still emerging, the results from multiple clinical trials can best be described as mixed. Nonetheless, these clinical studies have already provided important insights using ‘first-generation’ tools that may inform the development of effective and commercially viable biologics to treat tobacco-, cocaine-, and methamphetamine-use disorders.